	US 12,070,451 B2
	Sulfate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof
Yogeshwar Bachhav, Mumbai (IN); Wilfried Schwab, Werder (DE); Alexander Birkmann, Wuppertal (DE); Susanne Bonsmann, Cologne (DE); and Thomas Goldner, Wuppertal (DE)
Assigned to AiCuris GmbH & Co. KG, Wuppertal (DE)
Filed by AICURIS GMBH & CO. KG, Wuppertal (DE)
Filed on Jan. 26, 2022, as Appl. No. 17/585,145.
Application 17/585,145 is a continuation of application No. 16/464,189, granted, now 11,266,636, previously published as PCT/EP2017/080695, filed on Nov. 28, 2017.
Claims priority of application No. 16201009 (EP), filed on Nov. 28, 2016.
Prior Publication US 2022/0152009 A1, May 19, 2022
Int. Cl. A61K 31/4439 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C07D 417/12 (2006.01)

CPC A61K 31/4439 (2013.01) [A61K 9/0014 (2013.01); A61K 45/06 (2013.01); C07D 417/12 (2013.01)]

12 Claims

1. A sulfate salt of the free base of N-[5-(amino-sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide,

wherein said sulfate salt is characterized by having characteristic XRPD peaks at 5.6, 13.1, 19.7, 20.1, 22.1, 23.2 and 26.1 2theta when determined by using a compendial method as per “Ph. Eur” and/or “USP” methods.